# Berberine vs Metformin: What the Science Shows

Berberine and metformin both effectively lower blood sugar by activating the same cellular energy pathways, with rigorous head-to-head trials demonstrating they yield nearly identical short-term reductions in hemoglobin A1c (HbA1c). While metformin has the distinct advantage of decades of long-term safety data and remains the unquestioned gold-standard prescription for type 2 diabetes, berberine offers unique secondary benefits for cholesterol management but carries a higher risk of severe drug interactions. Neither compound is a miracle weight-loss drug, and individuals should not replace prescribed metabolic medications with dietary supplements without close medical supervision.

## Introduction to Metabolic Health and the AMPK Pathway

In the contemporary landscape of metabolic health, few comparisons are as frequently debated as the juxtaposition of metformin, a cornerstone pharmaceutical, and berberine, a plant-derived botanical extract. Both compounds sit at the center of discussions surrounding the management of type 2 diabetes mellitus, insulin resistance, metabolic syndrome, and cardiovascular disease risk reduction. As the global prevalence of metabolic dysfunction accelerates—with the International Diabetes Federation estimating that over 537 million adults globally are living with diabetes—the search for effective, well-tolerated therapeutic agents has intensified [cite: 1].

Metabolic syndrome is clinically defined as a multifactorial disorder characterized by a cluster of interrelated risk factors: abdominal obesity, systemic hypertension, hyperglycemia, hypertriglyceridemia, and low high-density lipoprotein cholesterol (HDL-C) [cite: 2, 3]. At the core of this syndrome is insulin resistance, a state wherein peripheral tissues fail to respond adequately to circulating insulin, forcing the pancreas to overproduce the hormone and ultimately leading to beta-cell exhaustion [cite: 2, 4, 5]. 

To understand why a botanical supplement and a synthetic prescription medication are so frequently compared by clinicians and researchers alike, one must examine the cellular mechanisms that govern human energy homeostasis. The human body manages its energy balance through a highly conserved enzymatic sensor known as AMP-activated protein kinase (AMPK). Often referred to in physiological literature as the body's "metabolic master switch," AMPK acts as a cellular fuel gauge. It constantly monitors the intracellular ratio of adenosine monophosphate (AMP) to adenosine triphosphate (ATP) [cite: 4, 6, 7]. 

When cellular energy is depleted—whether through physical exertion, caloric restriction, or pharmacological intervention—the AMP-to-ATP ratio rises. This energy deficit causes the AMPK switch to flip "on." Once activated, AMPK initiates a widespread physiological reallocation of resources. It forces the cell to halt energy-intensive anabolic processes, such as lipid synthesis and fat storage, and simultaneously upregulates catabolic processes that generate ATP, such as fatty acid oxidation and glucose uptake [cite: 4, 6, 8]. 

Both metformin and berberine exert their primary glucose-lowering and metabolic-regulating effects by activating this exact AMPK pathway. However, despite sharing this central molecular target, the two compounds originate from vastly different medical paradigms, possess distinct regulatory statuses, and navigate different biochemical pathways to achieve their results.

## The Origins: Ancient Botanical Roots vs. Pharmaceutical Milestones

The foundational difference between berberine and metformin extends beyond their molecular structure; it is deeply rooted in their historical development, regulatory oversight, and the depth of their respective clinical histories.

### The Evolution of Metformin
Metformin is an FDA-approved prescription medication that serves as the undisputed first-line pharmacological treatment for type 2 diabetes globally. Its origins, interestingly, are also botanical. The drug is derived from *Galega officinalis*, commonly known as the French lilac or goat's rue, a plant utilized in traditional European herbal medicine during the medieval period to relieve the intense, frequent urination associated with uncontrolled diabetes [cite: 9]. 

Researchers in the early 20th century isolated the active compounds within French lilac, identifying them as guanidines. Because natural guanidines proved too toxic for human clinical use, synthetic biguanides were developed in the 1920s [cite: 9]. Metformin, the safest of the biguanide class, was approved for the treatment of diabetes in Europe in the 1950s. However, it did not receive approval from the United States Food and Drug Administration (FDA) until 1994, following extensive safety profiling [cite: 9]. 

Today, metformin's clinical prominence is not merely a result of its efficacy in lowering blood glucose, but rather the monumental, multi-decade outcome studies supporting it. The landmark United Kingdom Prospective Diabetes Study (UKPDS) demonstrated unequivocally that metformin is the only oral anti-hyperglycemic agent capable of significantly reducing macrovascular complications, cardiovascular events, and all-cause mortality in overweight patients with type 2 diabetes over a 10-year follow-up period [cite: 9, 10]. This proven ability to extend life and prevent cardiac events is the bedrock of metformin's dominance in clinical guidelines.

### The Traditional History of Berberine
Berberine, conversely, is a naturally occurring, intensely yellow bioactive alkaloid compound belonging to the structural class of protoberberines. It is extracted from the roots, rhizomes, bark, and stems of several plant species, including *Berberis vulgaris* (European barberry), *Berberis aristata* (Indian barberry), *Hydrastis canadensis* (goldenseal), *Berberis aquifolium* (Oregon grape), and *Coptis chinensis* (Chinese goldthread) [cite: 9, 11, 12]. 

For over 3,000 years, berberine-containing plants have been a staple of traditional Chinese medicine (TCM) and Ayurvedic practice. Historically, it was not utilized for metabolic disease, but rather as a potent antimicrobial and anti-inflammatory agent to treat severe gastrointestinal ailments, bacterial diarrhea, dysentery, and topical wound infections [cite: 9, 11, 13]. 

It was not until 1986 that the hypoglycemic (blood-sugar-lowering) effects of berberine were formally documented in modern scientific literature, sparking a wave of modern pharmacological research [cite: 9]. In Western medical markets, berberine is classified strictly as a dietary supplement. Because it is not subject to the rigorous, multi-phase, pre-market approval processes mandated by the FDA for pharmaceutical drugs, it lacks the standardized dosing, guaranteed batch-to-batch purity, and exhaustive long-term safety data that characterize metformin [cite: 14, 15, 16]. Consequently, evidence for berberine relies on aggregate data from independent randomized controlled trials (RCTs) and systematic meta-analyses.

## Delineating the Molecular Mechanisms of Action

While the shorthand explanation frequently states that "berberine works just like metformin," this analogy is an oversimplification that undersells the complex pharmacology of the plant alkaloid. Both compounds activate AMPK, but they enter this metabolic pathway through different doors and trigger disparate secondary effects [cite: 17, 18].

[image delta #1, 0 bytes]



### How Metformin Operates
Metformin acts primarily within the liver (hepatic tissue). Upon entering the cell, it mildly and transiently inhibits Complex I of the mitochondrial electron transport chain [cite: 6, 7, 18, 19]. This highly specific disruption of cellular respiration impedes the mitochondria's ability to generate ATP efficiently. The resulting energy stress causes the intracellular AMP:ATP ratio to rise, which is immediately detected by the AMPK sensor. 

Once activated by metformin, AMPK forcefully suppresses hepatic gluconeogenesis, effectively commanding the liver to stop pumping excess glucose into the bloodstream [cite: 7, 14, 18]. Secondarily, metformin improves peripheral insulin sensitivity, allowing muscle cells to absorb circulating glucose more efficiently [cite: 14, 20]. Metformin also exhibits notable effects within the gut microbiome and has been shown to increase the secretion of endogenous glucagon-like peptide-1 (GLP-1) from intestinal L-cells, which aids in appetite regulation and insulin signaling [cite: 17, 18].

### The Pleiotropic Effects of Berberine
Berberine similarly inhibits mitochondrial Complex I to alter the cellular energy balance and activate AMPK, resulting in the same suppression of hepatic glucose output and enhancement of peripheral glucose uptake [cite: 4, 6, 18, 21]. However, berberine is described in pharmacology as a highly pleiotropic compound, meaning it operates across multiple physiological pathways and targets various cellular receptors simultaneously [cite: 4, 11, 17]. 

Beyond its core AMPK activation, berberine influences metabolic health through several distinct, well-documented mechanisms that metformin does not share:

1.  **Alpha-Glucosidase Inhibition:** In the gastrointestinal tract, berberine acts as an inhibitor of alpha-glucosidase, the enzyme responsible for breaking down complex carbohydrates into simple sugars. Similar to the mechanism of the prescription drug acarbose, this inhibition slows the rate of intestinal carbohydrate absorption, thereby blunting the rapid postprandial (after-meal) blood sugar spikes that damage endothelial tissue [cite: 17, 22].
2.  **PCSK9 Inhibition and Lipid Clearance:** One of berberine's most clinically significant mechanisms is its ability to inhibit Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9). PCSK9 is a protein that binds to and degrades low-density lipoprotein (LDL) receptors on the surface of liver cells. By inhibiting PCSK9, berberine prevents the degradation of these receptors, allowing the liver to continually clear "bad" LDL cholesterol from the bloodstream. This mechanism is conceptually identical to the action of highly expensive, injectable PCSK9-inhibitor drugs (like Repatha), albeit with less absolute potency [cite: 9, 18, 20].
3.  **Profound Microbiome Remodeling:** Leveraging its ancient history as an antimicrobial, berberine actively destroys specific pathogenic bacteria in the digestive tract while allowing beneficial strains to flourish. Research demonstrates that berberine shifts the microbiome toward species associated with improved metabolic function, significantly increasing populations of short-chain fatty acid (SCFA)-producing bacteria, such as *Akkermansia muciniphila*. This localized gut remodeling reduces systemic inflammation and improves the integrity of the intestinal barrier [cite: 14, 17, 18, 23].
4.  **SIRT1 and Epigenetic Modulation:** Emerging research indicates that berberine influences epigenetic modifications and supports SIRT1 activation, a pathway associated with mitochondrial biogenesis and cellular longevity, which adds another dimension to its metabolic profile [cite: 4, 7, 10].



## Clinical Evidence for Glycemic Control: The Head-to-Head Data

When evaluating dietary supplements, clinical evidence is often frustratingly weak, restricted entirely to murine (mouse) models, or based on isolated cell cultures. Berberine stands out as a rare exception in the nutraceutical space, boasting a remarkably robust body of human randomized controlled trials (RCTs) directly comparing its efficacy against leading pharmaceutical agents. 

### The Landmark Yin et al. Trial
The most widely cited benchmark in the comparison between berberine and metformin is a 2008 head-to-head randomized clinical trial led by Jun Yin and colleagues, published in the peer-reviewed journal *Metabolism* [cite: 9, 10, 12]. The researchers took 116 adult patients with newly diagnosed type 2 diabetes and randomly assigned them to receive either 500 mg of berberine three times daily or 500 mg of metformin three times daily over a 13-week period [cite: 10, 17, 18].

The results of the trial were staggering, turning heads within the conventional medical community. The glycemic outcomes between the botanical extract and the prescription drug were statistically equivalent [cite: 10, 12]. In the berberine cohort, HbA1c—the standard clinical measure of average blood sugar over a three-month period—dropped from a baseline of 9.5% down to 7.5%, representing a massive 2.0 percentage point reduction [cite: 10, 12, 17, 24, 25]. Fasting blood glucose plummeted from an average of 10.6 mmol/L to 6.9 mmol/L [cite: 24, 25, 26, 27]. Furthermore, postprandial blood glucose, fasting insulin levels, and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) all improved comparably across both treatment arms [cite: 12, 25, 27].

### Corroboration by Modern Meta-Analyses
Subsequent large-scale systematic reviews have repeatedly validated these early findings, proving that the Yin study was not an isolated anomaly. 

A comprehensive 2023 meta-analysis published in *JAMA Network Open* evaluated head-to-head and comparative trials, concluding that standard doses of berberine produced HbA1c reductions in the range of 0.9 to 1.5 percentage points over 12 to 24 weeks—an effect size that squarely matches standard metformin therapy [cite: 17]. The researchers noted that while fasting glucose reductions were matched, berberine occasionally demonstrated slightly more variability and superior performance in controlling postprandial glucose, a phenomenon directly attributed to its alpha-glucosidase inhibition in the gut [cite: 17].

More recently, a massive 2024 meta-analysis published in *Frontiers in Pharmacology* systematically assessed 50 RCTs encompassing a total of 4,150 participants [cite: 1, 10]. The rigorous analysis confirmed that berberine monotherapy alone significantly reduced fasting plasma glucose by a weighted mean difference (WMD) of -0.59 mmol/L and 2-hour postprandial blood glucose by an impressive -1.57 mmol/L [cite: 1, 10]. 

Interestingly, the *Frontiers* study also evaluated berberine as an adjunct therapy. When berberine was combined with conventional hypoglycemic drugs (such as standard metformin or sulfonylureas), it provided a powerful synergistic effect. The combination therapy drove HbA1c down by an additional 0.69% compared to the pharmaceutical drugs alone, while significantly improving systemic inflammatory markers, including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) [cite: 1].

## Lipid Control: Where Berberine Outperforms Metformin

While metformin and berberine may end in a statistical tie in the arena of pure blood sugar control, berberine holds a distinct, highly quantifiable advantage in managing lipids and resolving dyslipidemia.

Metformin is generally considered to be lipid-neutral in its primary mechanism of action. While patients taking metformin may occasionally see their cholesterol metrics improve over time, this is primarily an indirect, secondary benefit resulting from systemic weight loss, improved diet, and the correction of profound insulin resistance [cite: 18, 27]. Metformin simply does not aggressively target circulating cholesterol pathways.

Berberine, by contrast, operates directly on lipid clearance pathways through its inhibition of PCSK9 [cite: 9, 18, 27]. A comprehensive 2025 umbrella meta-analysis of randomized placebo-controlled trials analyzing the components of metabolic syndrome demonstrated berberine's unequivocal superiority in this specific domain [cite: 2, 24, 28]. The intervention yielded highly significant reductions across the lipid spectrum. The data showed consistent decreases in serum triglycerides (WMD: -0.367 mmol/L), total cholesterol (WMD: -0.451 mmol/L), and low-density lipoprotein cholesterol (WMD: -0.495 mmol/L) [cite: 2, 24, 27, 28]. Furthermore, berberine administration has been shown in several trials to modestly increase protective high-density lipoprotein (HDL-C) levels [cite: 2, 24, 28].

### Direct Implications for Metabolic Syndrome
This dual-action capacity—the ability to manage both glucose toxicity and lipid accumulation simultaneously—makes berberine an exceptionally attractive option for patients managing the full spectrum of metabolic syndrome [cite: 2, 3, 28, 29]. In comparative animal models mapping metabolic disease, researchers have concluded that while metformin is slightly more robust for pure glucose control, berberine is superior for reducing hyperlipidemia and combating liver fat accumulation [cite: 24, 30].

The following table summarizes the comparative effects of both agents on primary metabolic biomarkers based on aggregated clinical trial data:

| Biomarker Target | Metformin Impact | Berberine Impact | Mechanism of Superiority |
| :--- | :--- | :--- | :--- |
| **HbA1c (Long-term Glucose)** | High Reduction (-1.0% to -2.0%) | High Reduction (-0.9% to -2.0%) | Clinically Equivalent (Both via AMPK) |
| **Fasting Blood Glucose** | High Reduction | High Reduction | Clinically Equivalent |
| **Postprandial Glucose** | Moderate Reduction | High Reduction | Berberine (via Alpha-glucosidase inhibition) |
| **LDL Cholesterol** | Neutral / Minimal Indirect Effect | High Reduction (-0.30 to -0.49 mmol/L) | Berberine (via PCSK9 inhibition) |
| **Triglycerides** | Neutral / Minimal Indirect Effect | High Reduction (-0.35 to -0.56 mmol/L) | Berberine (Direct lipid metabolism) |
| **Insulin Resistance** | High Improvement | High Improvement | Clinically Equivalent |

*Data aggregated from the 2023 JAMA Network Open and 2024 Frontiers in Pharmacology meta-analyses [cite: 1, 2, 17].*

## Weight Loss: Debunking the "Nature's Ozempic" Myth

In recent years, an explosive trend across social media platforms has driven a massive surge in berberine sales by branding the supplement with a highly lucrative, yet scientifically fraught nickname: "Nature's Ozempic" [cite: 8, 11, 31, 32]. This narrative is fundamentally inaccurate, oversimplifies complex pharmacology, and sets patients up for extreme clinical disappointment [cite: 8, 11, 19, 33].

### The Disconnect in Pharmacological Mechanisms
To understand why the comparison fails, one must understand how modern weight-loss drugs operate. Ozempic and Wegovy (both utilizing the active ingredient semaglutide) belong to a class of powerful prescription medications known as glucagon-like peptide-1 (GLP-1) receptor agonists [cite: 8, 11, 13]. These synthetic hormones act directly on receptors in the brain to drastically suppress appetite and slow gastric emptying in the stomach [cite: 11, 13, 33]. The result is a profound, hormonally enforced caloric deficit. 

Berberine does not work this way. While there is minor preclinical evidence suggesting berberine may prompt a very slight endogenous release of GLP-1 from intestinal L-cells, its dominant mechanism remains AMPK activation [cite: 8, 17, 18]. Berberine works to optimize how cells *utilize* energy, improving metabolic flexibility and insulin sensitivity; it is not a primary appetite suppressant, nor does it paralyze gastric emptying [cite: 8, 13, 33].

### The Reality of Weight Loss Outcomes
When examining clinical trial outcomes, the discrepancy in weight loss magnitude between berberine and true GLP-1 agonists is stark. Both metformin and berberine produce mild, statistically significant modifications to body mass, largely by improving insulin sensitivity, reducing the body's tendency to store fat, and mitigating insulin-driven sugar cravings [cite: 13, 29]. However, neither functions as a primary, top-tier weight-loss agent [cite: 27, 29, 34].

In the landmark STEP 1 clinical trials for semaglutide (Wegovy), participants experienced an average weight loss of approximately 15% of their total body weight over 68 weeks—equating to 24 to 37 pounds (11 to 17 kg) of mass reduction [cite: 8, 34, 35]. 

By contrast, umbrella meta-analyses tracking over 17,000 human subjects reveal that individuals taking therapeutic doses of berberine (770 to 1,500 mg daily) for two to six months lose an average of only 2 to 5 pounds (roughly 1 to 2.5 kg), representing a mere 2% to 4% reduction in total body weight [cite: 8, 27, 34, 35, 36]. Metformin performs similarly; the legendary Diabetes Prevention Program study found that metformin produced an average weight loss of just 4.6 pounds (2.1 kg) over a nearly three-year period compared to placebo [cite: 10, 29]. 

To expect prescription-level GLP-1 weight loss from a botanical AMPK activator is a fundamental error [cite: 8, 33]. A patient utilizing berberine or metformin will likely see a modest reduction in waist circumference and visceral adiposity, but this will primarily serve to support, rather than replace, dedicated dietary and lifestyle interventions [cite: 29, 35, 36]. 

## Applications Beyond Diabetes: Polycystic Ovary Syndrome (PCOS)

Beyond standard glycemic control, the therapeutic overlap between berberine and metformin is most evident in the management of Polycystic Ovary Syndrome (PCOS). PCOS is a complex endocrine disorder affecting approximately 170 million women worldwide, characterized by ovulatory dysfunction, hyperandrogenism (elevated testosterone), and profound systemic insulin resistance [cite: 3, 5, 29].

Metformin has been utilized off-label for decades as a foundational treatment for PCOS to help regulate menstrual cycles and combat the driving force of insulin resistance [cite: 29, 37]. However, recent comparative clinical trials suggest that berberine may possess genuine, distinct advantages for this specific patient population. 

Because women with PCOS frequently suffer from severe dyslipidemia in addition to insulin resistance, berberine's dual-action ability to sensitize cells to insulin while aggressively lowering LDL cholesterol and triglycerides makes it highly effective [cite: 3, 24, 38]. In several head-to-head trials, berberine matched metformin's ability to improve ovulation rates but slightly outperformed the pharmaceutical in reducing elevated testosterone levels, decreasing waist-to-hip ratios, and correcting lipid profiles [cite: 3, 24, 29]. For women unable to tolerate the gastrointestinal side effects of high-dose metformin, berberine has emerged as a scientifically validated, holistic management tool [cite: 37, 38].

## Side Effects, Safety Profiles, and Nutrient Depletion

Any compound potent enough to alter human cellular metabolism is potent enough to cause adverse effects. While meta-analyses consistently demonstrate that both metformin and berberine possess highly favorable safety profiles with no significant organ toxicity, their specific side effect profiles diverge in clinically meaningful ways [cite: 16, 39, 40, 41].

### Gastrointestinal Disturbances
Because both compounds interact heavily with the gut microbiome and alter intestinal glucose absorption, localized gastrointestinal distress is the most commonly reported side effect for both agents [cite: 18, 24, 42]. 
*   **Metformin** side effects skew heavily toward diarrhea, nausea, bloating, and abdominal cramping. These effects are often dose-limiting for patients and are particularly severe when initiating therapy, though they tend to improve with time or by switching to extended-release formulations [cite: 10, 14, 24]. 
*   **Berberine** produces transient gastrointestinal adverse effects in approximately 34.5% of users. However, because of its ancient history as an anti-diarrheal medicine, its side effects run in the opposite direction; it frequently causes severe constipation in sensitive users, alongside general cramping and flatulence [cite: 10, 39, 42, 43].

### The Vitamin B12 Deficiency Risk
One of berberine's most meaningful, yet rarely discussed, clinical advantages over metformin is its lack of impact on Vitamin B12 absorption. The medical literature has firmly established that long-term metformin use interferes with the calcium-dependent absorption of Vitamin B12 in the terminal ileum [cite: 17, 44, 45]. This nutrient depletion is a clinically under-monitored phenomenon that can lead to insidious fatigue, macrocytic anemia, and irreversible peripheral neuropathy, requiring patients on metformin to undergo regular B12 screening and supplementation [cite: 17, 44, 45]. Berberine does not disrupt B12 pathways, making it an appealing option for those concerned about long-term nutrient depletion [cite: 17].

### Lactic Acidosis and Hypoglycemia
A rare but highly severe risk associated with metformin is lactic acidosis—a dangerous buildup of lactic acid in the bloodstream that requires immediate medical intervention. This risk is primarily confined to individuals with pre-existing severe renal (kidney) or hepatic (liver) impairment, which is why metformin requires strict medical monitoring [cite: 14, 44, 45]. Berberine has not been linked to lactic acidosis in human trials [cite: 45].

Crucially, neither metformin nor berberine acts as an insulin secretagogue (like sulfonylurea drugs), meaning that when taken independently, neither compound significantly increases the risk of hypoglycemia (dangerously low blood sugar). Their glucose-lowering effects are strictly dependent on the presence of hyperglycemia [cite: 16, 39, 41]. 

## Pharmacokinetics and Dangerous Drug Interactions

While the supplement industry often markets berberine as a "safe, natural alternative," this framing ignores the strict realities of pharmacokinetics. Berberine commands immense respect regarding its interaction with the human liver [cite: 18, 33, 46].

Metformin is primarily excreted unchanged by the kidneys, meaning it largely avoids interacting with the liver's metabolic enzymes. Berberine, however, is a known, potent inhibitor of the Cytochrome P450 enzyme system—specifically inhibiting the crucial liver enzymes CYP3A4, CYP2D6, and CYP2C9 [cite: 17, 18, 47]. 

These specific enzymes are responsible for metabolizing and clearing a vast array of common prescription medications from the body. If a patient takes berberine alongside these medications, the berberine effectively blocks the liver's ability to process the drugs, slowing their clearance and dangerously raising their concentrations in the blood [cite: 17, 18]. 
Clinically significant interactions include:
*   **Statins:** Increased risk of severe muscle pain and liver toxicity.
*   **Immunosuppressants:** Such as cyclosporine, leading to toxic accumulation.
*   **Blood Thinners:** Altering clotting times and increasing bleeding risks.
*   **Macrolide Antibiotics and Antihistamines:** Risk of altered systemic effects.

Any patient taking prescription medications metabolized by the liver must consult a physician or clinical pharmacist before initiating berberine therapy [cite: 18, 44, 47]. 

## The Bioavailability Challenge and Advanced Formulations

A persistent pharmacological hurdle with standard berberine hydrochloride (HCl) is its notoriously poor oral bioavailability. It is estimated that less than 1% of standard berberine HCl enters the systemic bloodstream when swallowed [cite: 23, 27, 48]. The vast majority remains in the gastrointestinal tract, where it is eventually excreted [cite: 23]. 

While this massive localized gut concentration is highly effective for antimicrobial microbiome remodeling and stimulating local intestinal GLP-1 receptors, the poor systemic absorption limits the compound's reach to peripheral muscle and liver tissues [cite: 23, 48]. To overcome this barrier, massive dosing regimens are required—typically 500 mg taken three times daily (1,500 mg total) with meals—which directly drives the high rates of gastrointestinal cramping and constipation [cite: 4, 18, 43].

To solve the absorption dilemma, both the nutraceutical and pharmaceutical industries are actively developing advanced delivery mechanisms:

### Berberine Phytosome Technology
The supplement industry has widely adopted **Berberine Phytosome** technology. This delivery mechanism involves encasing the raw berberine molecule within a lipid (fat-soluble) matrix, typically utilizing sunflower phospholipids [cite: 23, 49, 50]. By mimicking the structure of human cell membranes, the phytosome allows the berberine to pass through the intestinal wall much more efficiently. 

Clinical pharmacokinetic studies indicate that phytosome technology increases berberine's bioavailability by 5 to 9.6 times compared to standard HCl extracts [cite: 49, 51, 52]. This enhanced absorption allows users to take a significantly lower daily dose (e.g., 550 mg daily) while achieving the same systemic metabolic markers, which drastically reduces the risk of gastrointestinal side effects and improves patient compliance [cite: 49, 50, 53]. 

### Investigational Pharmaceuticals: HTD1801
The pharmaceutical industry is also actively attempting to patent and improve the berberine molecule. A notable advancement is the development of berberine ursodeoxycholate (HTD1801), an investigational, proprietary ionic salt combining berberine with ursodeoxycholic acid [cite: 54, 55, 56]. 

Designed to dramatically improve intestinal solubility and simultaneously target both AMPK activation and the NLRP3 inflammasome, HTD1801 recently underwent rigorous testing. A phase 2 randomized, double-blind clinical trial published in *JAMA Network Open* in March 2025 evaluated 113 patients with type 2 diabetes over 12 weeks [cite: 54, 55, 57]. The results were highly promising, showing significant, dose-dependent reductions in HbA1c—up to a -1.0% change from baseline in the high-dose (1000 mg twice daily) group—alongside marked improvements in liver fat and lipid markers [cite: 55, 57]. While HTD1801 is still navigating the FDA trial process and possesses Fast Track designation for specific liver conditions, the robust data from these trials highlight the mainstream scientific community's ongoing validation of berberine's core molecular efficacy [cite: 54, 56].

## Clinical Guidelines and the Hierarchy of Evidence

If berberine matches metformin in blood sugar reduction and clearly outperforms it in lipid management, a logical question arises: why is berberine not the standard medical therapy prescribed by doctors? The answer lies in the strict hierarchy of medical evidence and the specific criteria required for inclusion in clinical guidelines.

Current, evidence-based guidelines from all major medical authorities—including the American Diabetes Association (ADA), the American College of Physicians (ACP), the Endocrine Society, and the American Association of Clinical Endocrinology (AACE)—explicitly establish metformin as the foundational, first-line oral therapy for type 2 diabetes. Berberine is conspicuously absent from all major treatment algorithms [cite: 16, 58, 59, 60].

This omission is not due to a lack of efficacy in lowering surrogate biomarkers like HbA1c or fasting glucose. Rather, it reflects a critical lack of long-term mortality data. Modern medical guidelines prioritize medications that have proven they can extend human life. Metformin has the backing of monumental, multi-decade trials proving it statistically reduces all-cause mortality, prevents myocardial infarctions (heart attacks), and lowers stroke risks [cite: 17, 25, 58, 59]. 

By contrast, berberine trials are almost exclusively short-term (lasting three to six months), utilize relatively small sample sizes (rarely exceeding a few hundred patients per trial), and are heavily concentrated in specific geographical regions [cite: 17, 19, 32, 58]. While the surrogate marker data is incredibly promising, no study has yet demonstrated that berberine prevents cardiovascular death or slows chronic kidney disease progression over a ten-year horizon [cite: 25, 58, 59]. Until massive, multi-year, internationally diverse cardiovascular outcome trials are conducted on berberine, it will remain categorized as a complementary or adjunctive therapy rather than a guideline-directed standard of care [cite: 16, 47, 58]. 

## Can You Take Berberine and Metformin Together?

A frequent query among patients currently prescribed metformin is whether berberine can be added to their regimen to enhance metabolic results. 

Mechanistically, combining the two compounds can produce a powerful synergistic effect. Because they activate AMPK via slightly different cellular mechanisms and berberine exerts additional control over lipid clearance and gut alpha-glucosidase, the combination can drive blood glucose and insulin resistance down further than either compound administered alone [cite: 1, 24, 26]. The dual action is particularly appealing for managing the mixed dyslipidemia commonly seen in advanced metabolic syndrome [cite: 24, 26].

However, combining these agents demands strict, ongoing medical supervision for two critical reasons:
1.  **Additive Hypoglycemia:** Stacking two potent hypoglycemic agents, particularly alongside other medications like sulfonylureas or insulin, significantly increases the risk of pushing blood sugar too low, resulting in dangerous, symptomatic hypoglycemia [cite: 15, 17, 37, 60].
2.  **Pharmacokinetic Interference:** There is clinical evidence indicating that berberine may alter the systemic absorption and blood concentrations of metformin [cite: 20]. When taken concurrently, the berberine may reduce the bioavailability of the metformin, meaning the prescription drug may not act as predictably or effectively [cite: 20, 24]. 

Patients are strongly advised never to discontinue a prescribed metformin regimen in favor of an over-the-counter berberine supplement, nor should they combine the two, without explicit consultation and regular blood monitoring from their endocrinologist or primary care physician [cite: 7, 37, 60, 61].

## Bottom line

The clinical evidence confirms that berberine is a highly potent botanical compound capable of matching metformin in lowering fasting blood sugar and HbA1c, with the distinct added benefit of significantly improving cholesterol profiles via PCSK9 inhibition. However, berberine is not an over-the-counter replacement for semaglutide (Ozempic) for massive weight loss, nor does it possess the multi-decade cardiovascular mortality data that cements metformin as the unquestioned gold standard in clinical guidelines. For individuals seeking metabolic support without a prescription, berberine is a scientifically validated tool, but its potential for gastrointestinal upset and severe drug interactions means it must be utilized with the same respect afforded to traditional pharmaceuticals.

## Sources
1. [Berberine and Metabolic Syndrome (PMC 2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12307485/)
2. [Berberine vs Metformin Review (YourHealthier 2026)](https://yourhealthier.com/blogs/blog/berberine-vs-metformin)
3. [Berberine vs Metformin: Pros & Cons (Ubie Health)](https://ubiehealth.com/doctors-note/berberine-versus-metformin-natures-pros-cons-bg-4232e5)
4. [Metformin vs Berberine Meta-Analysis (PMC 2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5839379/)
5. [Berberine vs Metformin for Blood Sugar (Dr. Ruscio)](https://drruscio.com/berberine-vs-metformin/)
6. [Berberine vs Metformin: Clinical Insights (ClarityTx 2026)](https://www.claritytx.ai/insights/berberine-vs-metformin-what-the-evidence-says)
7. [Berberine vs Metformin: Are They the Same? (Cleveland Clinic 2025)](https://health.clevelandclinic.org/berberine-vs-metformin)
8. [Metformin vs Berberine Differences (BuzzRx)](https://www.buzzrx.com/blog/metformin-vs-berberine-similarities-and-differences)
9. [Berberine vs Metformin for Weight Loss Review (Oregon State)](https://blogs.oregonstate.edu/sunny/berberine-vs-metformin-for-weight-loss-review-2026-scam-or-legit-natural-alternative/)
10. [Combining Berberine and Metformin (GoodRx)](https://www.goodrx.com/conditions/weight-loss/can-you-take-berberine-and-metformin-together)
11. [AMPK Activation by Berberine and Metformin (PMC 2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4262417/)
12. [How They Work: Same Target, Different Paths (Meo Nutrition 2025)](https://meonutrition.com/blogs/article/berberine-vs-metformin)
13. [Berberine vs Metformin AMPK Protocol (VerateNet 2026)](https://veratenet.com/blogs/the-science/berberine-vs-metformin-in-2026-the-ampk-activation-protocol)
14. [AMPK and Berberine Truths (Tonum 2025)](https://tonum.com/blogs/useful-knowledge/are-ampk-and-berberine-the-same-thing-surprising-powerful-truth)
15. [Distinct Modes of AMPK Activation (PMC 2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10151516/)
16. [Is Berberine Really Nature's Ozempic? (News-Medical 2025)](https://www.news-medical.net/health/Is-Berberine-Really-e2809cNaturee28099s-Ozempice2809d-What-Science-Says.aspx)
17. [Is Berberine Nature's Ozempic? (Sharp Health 2023)](https://www.sharp.com/health-news/is-berberine-natures-ozempic)
18. [Berberine TikTok Trend (The Guardian 2023)](https://www.theguardian.com/us-news/2023/jun/11/berberine-weight-loss-supplement-tiktok-ozempic)
19. [Forget TikTok Claims: Nature's Ozempic (Naturopathic.org 2023)](https://naturopathic.org/news/645178/Forget-TikTok-Claims-Natures-Ozempic-is-No-Such-Thing-Experts-Say.htm)
20. [Weight Loss Trends: Ozempic and Berberine (Innova Market Insights)](https://www.innovamarketinsights.com/trends/weight-loss-trends/)
21. [Can I Take Berberine With Metformin? (Bolt Pharmacy 2026)](https://www.boltpharmacy.co.uk/guide/can-i-take-berberine-with-metformin)
22. [Berberine and Metformin Interaction (SingleCare 2025)](https://www.singlecare.com/blog/berberine-and-metformin/)
23. [Side Effects of Metformin and Berberine Together (Cambridge 2026)](https://teaching.eng.cam.ac.uk/sites/teaching.eng.cam.ac.uk/themes/sites/?id=side-effects-of-metformin-and-berberine-together-2026-safety-and-interaction-report)
24. [Berberine Clinical Trials (WithPower)](https://www.withpower.com/trial/phase-metabolic-syndrome-7-2019-0f73a)
25. [Berberine Efficacy in Obesity (MDPI 2022)](https://www.mdpi.com/1420-3049/27/4/1351)
26. [What Clinical Trials Has Berberine Been A Part Of? (Dr. Oracle)](https://www.droracle.ai/articles/152261/what-clinical-trials-has-berberine-been-a-part-of)
27. [Effect of Berberine on PCOS (ClinicalTrials.gov)](https://clinicaltrials.gov/study/NCT01138930)
28. [Completed Clinical Trials on Berberine (ResearchGate)](https://www.researchgate.net/figure/Completed-clinical-trials-with-berberine-in-the-metabolic-syndrome-based-on_tbl1_358702638)
29. [Berberine vs Ozempic for Weight Loss (PlexusDx 2026)](https://plexusdx.com/blogs/learn/berberine-vs-ozempic-does-natures-alternative-truly-measure-up-for-weight-loss-vs-plexusdx)
30. [The Truth Behind Nature's Ozempic (Health First Hagerstown)](https://www.healthfirsthagerstown.com/blogs/berberine-the-truth-behind-natures-ozempic-and-weight-loss)
31. [Berberine vs Ozempic Science (Organic Basic Food 2026)](https://www.organicbasicfood.com/blog/berberine-vs-ozempic-natures-glp1-blood-sugar-weight)
32. [Berberine Mechanisms & Ozempic Claims (News-Medical 2025)](https://www.news-medical.net/health/Is-Berberine-Really-e2809cNaturee28099s-Ozempice2809d-What-Science-Says.aspx)
33. [Berberine vs Semaglutide (Fay Nutrition 2025)](https://www.faynutrition.com/post/berberine-vs-semaglutide-natures-ozempic)
34. [Berberine JAMA Network Open Meta-Analysis (ClarityTx 2026)](https://www.claritytx.ai/insights/berberine-vs-metformin-what-the-evidence-says)
35. [Natural vs Pharmaceutical Solutions (Eternal Elixir 2026)](https://eternalelixir.com.au/berberine-vs-metformin-a-comparison-of-natural-vs-pharmaceutical-solutions-for-metabolic-health/)
36. [Berberine vs Metformin Lipid Improvements (Instalab 2026)](https://instalab.com/answers/berberine-vs-metformin)
37. [Metformin and Berberine Comparative Review (PMC 2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5839379/)
38. [Berberine and Metformin Pharmacodynamics (Biomed Pharmacother 2023)](https://pubmed.ncbi.nlm.nih.gov/37094549/)
39. [Berberine Dosage and Efficacy (YourHealthier 2026)](https://yourhealthier.com/blogs/blog/berberine-vs-metformin)
40. [Berberine HbA1c Reduction Meta-Analysis (Bolt Pharmacy 2026)](https://www.boltpharmacy.co.uk/guide/berberine-type-2-diabetes-metaanalysis-hba1c-reduction)
41. [Systematic Assessment of Berberine (Frontiers 2024)](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1455534/full)
42. [Berberine: Natural Alternative to Metformin? (Age Immune 2026)](https://ageimmune.com/berberine-natural-alternative-to-metformin/)
43. [Rates of Adverse Effects of Berberine (Dr. Oracle 2025)](https://www.droracle.ai/articles/229620/what-are-the-rates-of-adverse-effects-and-long-term)
44. [Berberine Side Effects Overview (PubMed 2023)](https://pubmed.ncbi.nlm.nih.gov/36999891/)
45. [Common Side Effects of Berberine (Dr. Oracle 2026)](https://www.droracle.ai/articles/953543/what-are-the-common-side-effects-and-safety-concerns)
46. [Safety Outcomes of Berberine (Frontiers 2025)](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1572197/full)
47. [Berberine Phytosome vs Berberine HCl (Nature Made 2024)](https://www.naturemade.com/blogs/health-articles/berberine-phytosome-vs-berberine-hcl)
48. [Berberine and Berberine Phytosome (Landys Chemist 2024)](https://www.landyschemist.com/berberine-and-berberine-phytosome)
49. [Berberine Benefits and Types (iHerb 2024)](https://www.iherb.com/blog/berberine-benefits-types/1940)
50. [Bioavailability Dilemma of Berberine (Herbiflix 2026)](https://us.herbiflix.com/blogs/news/berberine-phytosome-vs-berberine-hcl)
51. [Berberine vs Phytosome Differences (Swiss Peak Health 2026)](https://swisspeakhealth.com/blogs/sustained-energy/berberine-vs-berberine-phytosome-what-is-the-difference)
52. [Clinically Studied Benefits of Phytosome (Nature Made 2024)](https://www.naturemade.com/blogs/health-articles/berberine-phytosome-vs-berberine-hcl)
53. [Berberine Phytosome in PCOS Trial (Frontiers 2023)](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1269605/full)
54. [Berberine Phospholipid Clinical Trial (Eur Rev Med Pharmacol Sci 2023)](https://www.europeanreview.org/article/33142)
55. [Berberine Phytosome Presentation (YouTube 2023)](https://www.youtube.com/watch?v=WsVVusk8_HY)
56. [Berberine Clinical Effects (PMC 2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8107691/)
57. [Berberine B12 Comparison (ClarityTx 2026)](https://www.claritytx.ai/insights/berberine-vs-metformin-what-the-evidence-says)
58. [Pros and Cons of Berberine and Metformin (Apkamuaalij 2026)](https://www.apkamuaalij.com/blogs/berberine-vs-metformin-how-do-they-compare)
59. [Berberine vs Metformin Cleveland Clinic (Cleveland Clinic 2025)](https://health.clevelandclinic.org/berberine-vs-metformin)
60. [Berberine Properties and Deficiencies (The American Journals 2025)](https://theamericanjournals.com/index.php/tajmspr/article/view/5896)
61. [Berberine Metformin GI Data (Instalab 2026)](https://instalab.com/answers/berberine-vs-metformin)
62. [Berberine Side Effects vs Metformin (Meo Nutrition 2025)](https://meonutrition.com/blogs/article/berberine-vs-metformin)
63. [Berberine Side Effects (Fay Nutrition 2025)](https://www.faynutrition.com/post/berberine-benefits-uses-side-effects-and-risks-for-natures-ozempic)
64. [Berberine Health Benefits (WebMD)](https://www.webmd.com/obesity/berberine-health-benefits)
65. [Does Berberine Cause Constipation? (Bolt Pharmacy 2026)](https://www.boltpharmacy.co.uk/guide/does-berberine-cause-constipation)
66. [Uses and Dosages of Berberine (Dr. Oracle 2025)](https://www.droracle.ai/articles/289381/what-are-the-uses-and-dosages-of-berberine-particularly)
67. [Berberine Weight Loss Meta-Analysis (YourHealthier 2026)](https://yourhealthier.com/blogs/blog/berberine-vs-metformin)
68. [Berberine vs Metformin Weight Data (Dr. Ruscio)](https://drruscio.com/berberine-vs-metformin/)
69. [Comparison Berberine Metformin (Mental Momentum 2026)](https://research.mental-momentum.ai/r/comparison-berberine-metformin-metabolic-m1dptf)
70. [Berberine vs Metformin Longevity (VitalWhys 2026)](https://www.vitalwhys.com/articles/berberine-vs-metformin-longevity-research)
71. [Berberine vs Metformin for Weight Loss Review (Oregon State 2026)](https://blogs.oregonstate.edu/sunny/berberine-vs-metformin-for-weight-loss-review-2026-scam-or-legit-natural-alternative/)
72. [Berberine and Clinical Guidelines (Dr. Oracle 2026)](https://www.droracle.ai/articles/1100109/how-should-berberine-be-dosed-monitored-and-what-are)
73. [Absence of Berberine in Guidelines (Dr. Oracle 2026)](https://www.droracle.ai/articles/1066222/in-an-adult-with-type-2-diabetes-mellitus-who)
74. [Meta-Analysis of BBR for T2DM (Frontiers 2024)](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1455534/full)
75. [Berberine on Metabolic Syndrome Indicators (Frontiers 2025)](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1572197/full)
76. [ADA 2025 Guidelines Analysis (Exploration Pub 2025)](https://www.explorationpub.com/Journals/eemd/Article/101428)
77. [Key Findings 2024 Meta-Analysis (Frontiers in Pharmacology)](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1455534/full)
78. [2023 Meta-Analysis in Biomedicine & Pharmacotherapy (PubMed)](https://pubmed.ncbi.nlm.nih.gov/37094549/)
79. [Berberine Ursodeoxycholate Review (PMC 2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12307485/)
80. [Endocrine Society on Berberine (HealthCentral 2025)](https://www.healthcentral.com/condition/obesity/berberine-for-weight-loss)
81. [Endocrine Society Obesity Guidelines (PMC 2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12160363/)
82. [Guidelines and Berberine Data (J-Stage 2025)](https://www.jstage.jst.go.jp/article/endocrj/66/1/66_EJ18-0109/_html/-char/ja)
83. [Blood Sugar Target Guidelines (U-Tokyo 2025)](https://www.uf.a.u-tokyo.ac.jp/chiba/pannellum/pannellum.htm?config=/%5C/0.0o0o.sbs/article/bs/jdaAP7UAc0EblYSx)
84. [Endocrine Society Guidelines (Endocrine.org 2024)](https://www.endocrine.org/news-and-advocacy/news-room/2024/people-with-type-2-diabetes-who-eat-low-carb-may-be-able-to-discontinue-medication)
85. [Ji et al 2025 Trial Details (Eternal Elixir 2026)](https://eternalelixir.com.au/berberine-vs-metformin-a-comparison-of-natural-vs-pharmaceutical-solutions-for-metabolic-health/)
86. [Ji et al 2025 Berberine Dosage (YourHealthier 2026)](https://yourhealthier.com/blogs/blog/berberine-dosage-guide)
87. [Berberine Ursodeoxycholate for T2D (JAMA Netw Open 2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11877176/)
88. [Berberine Ursodeoxycholate Trial Data (ResearchGate 2025)](https://www.researchgate.net/publication/389519975_Berberine_Ursodeoxycholate_for_the_Treatment_of_Type_2_Diabetes_A_Randomized_Clinical_Trial)
89. [HTD1801 Background (CMH Journal 2025)](https://www.e-cmh.org/journal/view.php?doi=10.3350/cmh.2025.0145)
90. [ADA 2025 Standards of Care and Berberine (Fella Health 2025)](https://www.fellahealth.com/guide/is-berberine-a-glp-1-agonist)
91. [ADA 2025 Guidelines Context (HealthGuidance 2026)](https://jobs.kathmandu.gov.np/images/?p=My-30-day-Experience-with-Berberine-for-Weight-Management-n02Nc3ymb5ZMM)
92. [Berberine in Diabetes Guidelines (Dr. Oracle 2025)](https://www.droracle.ai/articles/628029/is-berberine-safe-for-individuals-with-diabetes-diabetes-mellitus)
93. [Efficacy and Guidelines Absence (Dr. Oracle 2025)](https://www.droracle.ai/articles/256088/what-are-the-efficacy-and-potential-side-effects-of)
94. [Diabetes and Dietary Supplements (NCCIH NIH)](https://www.nccih.nih.gov/health/diabetes-and-dietary-supplements-what-you-need-to-know)

**Sources:**
1. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHdKIdbDHPGrPwrhIhQOx1qmDjGPVfY1_S72po71THJFbxWTe4IqZX9Hlqt8QcMNDjhH3pPF11kaTQO2pqlnuGiiQntl23i6azFVJZEbx0p_JJTMMBEyUYsHnoif-3_QJPjoDXtzfn4UajLW7uurGbLeoihXBTi5npeMRo9HTqdEyTog6VLkyZY814XrlMX3CU=)
2. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEwdjwcd5BWSDpeyDeMNJHihtS7Vzgoug0it8GaJy0DUVEScIXpevWmG3cnnqgZ03o91ubPtfepLGPXN6fOfmQWM3zR4H8hM2K1ZB5pcmNGjVTXHV5Zu-IVrcJEG0bA2SppzwoeYs5NtQ==)
3. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF3z_Job1umrKANlK65A3cUFAXTrV9nTiW-AyRoqaDzQ2O1mSTSQXNpA916lxdwDkS4LiQOcfsHV7onEZVTKpMt1Jx3yykJwywENbr2W5uXYBI3S3zfao0GFAH5xRLu)
4. [tonum.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF5C_K6lHqn-7mcUYo37s6EqeoVhxGmNCxxOa0wPeaHBnBQl8xnfWj0IPNzJ3sUP64sV7Aneorn4jdoAifCxCfRSj3k3dvl8A4CMbnE7Etkax-3-R3GMyrhUAJebQljah7DMOjDdhlCa316MW8ZxM1hhVTbLZMOKsibkOqmcz2zCPntLuURzuzKgxzD3ASDqxSGGaz49skikxAnocqNow==)
5. [endocrine.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHwvocGxrcEirZXHtipkqyWpMae0tHiFSjV5znkxbSwKVaaFJGwK8X7L4mRStZajRo88X4iEXnAOK9y4jurgiFvfTZ6dBgZ-3g4Lsf5cttkSEa6B0vJnn9SBB6lKs2U3dnzc9rtP_WcVCxxdFUUef39GxRyCNJ2UwLKtNpN_66e9XbRgoNQMeEZm9KabUDogvspBxDEJ9lcbPZktFi1jhcRX98-igrkwgifLzakANB3hCPFDE8dXkxWpaNsN8nP6E5V7gO4)
6. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGoBBObpn88ekL4vDhtnz62llq0k3_Y4RNkEjUT0qkrBZklP4j42vuirGM6YV6t1pSmJd1V7t3O9Zv-XuYS83GRm9uLlJ-oXRhHpRhk1Tl_4JpQrZjRS6j_tReTY2g7tXBoeAOzoWOy)
7. [veratenet.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG8MswQm6AAKOgiVE4DkRYDXPOkif1kytSFIW7MsLTxCGZ5aR1qyp5tV6COXjiURMGkwAChASkHh27pbNkjlPEqa7P57dEovqN1toFKObbE7zUNw_Mvr2h3CGjmvHKyKGGTe62KHyA144b7p-fd-IeLQHbGG-il5VXgGlPdcY97Ch0m15ZS4soTn1mKvaKPcnIwEmukiPzawTY=)
8. [organicbasicfood.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFAXzaum96BBSQbsuLhk2IsJz6_cm9FmnN5iLJ8wPSNZX2Hh-GFF-Tc-BO-ZM-jY0Ar_z_nLIvaORjr0BbemS7vFb_gCazVlFNXGFbwhw51tiBjQvLzUWeNsPYn79lCvxU1n1vxBbPAb8blHCr_7JmjICTkmMIwAeeCd5tzi-VUFzvuDG1kz3hbxEyCuqAkNrA=)
9. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEGZwNrkE0sgKff0pjoo3-Le9idirEf9s9vzOmGCnX98-oW3cxV81WhIzeS-8lAF0Nz9hrQBpP7iaJOVm5h1wj4DiKotC7KekD0Nl_Iou2GkmgLdeW6jLMhqrpHgzZkVbo-uGfvUiym)
10. [yourhealthier.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG0jYTHEpEx4PBU0BBkqVw2mN_blIHSMLxDSSC8nTPgfHId-3WZtU-ftJ8uJ1BV4S33L3b91FOQh1bnuWAxeoCUai4eB0p0LSWChWkBxtLBMJSwsW6dArygmX5DxMch_2w107HlgAFCBn8Q1bh_bgi-Hw==)
11. [news-medical.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFPk3jmiBKVXKRz9MYIomcMnAB8vypmyB26vIt5XDb5vv9TQqDfE0ljJtoEvVx4gRX5UNzqxj5poHa1JnvTYEivUey_qJ_ODd4RPTzOAuF34MNNJuoSRIWzIEkWzLGxOLlD1t_jgCR00XYDW1pZLKJ2F8ChzhpsfPmpjhtdtmsGcvTHf7G3l5tgq_tKU8xjLFFSrTyypjeyonDeyfOm4V5oEKQG4Ubz)
12. [ageimmune.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGJ4eGvwdIr1Pcf27e1fu647hBnVViC1Vo28QXkSi6Vd6gHJfnQyAsPbDe8rEYEivGmmD3k0SIhCH3W-mRecnGP-OaL8otU66iHnsuny7wE37nBuZDlq6blAOiy1z2MfWSbbzQmX_tWSNy_lZPHgk_kOLrHHhCl4w==)
13. [sharp.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE0BgXx86v0jFyWVAWfp-ZRayWtxcgOwneM1Cw2t-UXPRlsBruc0_BaRs8GQRRrRpHJrNj_9hrJqOjwbQjkRoEjPjsl_8JPXgsPxkjtgduT6ALQYdNL-yaubNBkbp9HHkCcFf3o3xn4pBYaLaQEabxpuobNWw==)
14. [clevelandclinic.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEY-qtzmwoWRz7arIWe735dWqpcccQm48D8he_iQrRIiGYZ_D7vxVdyPPUdFxzeTaFP8ZU9xSaqWnV4QniXm0Vi-ukHv5wFgWpb5z78v-CAlfUPKqVke19hxQDwFcaNb-JK_MisRs2-GyuG22IDW0Y=)
15. [goodrx.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGEKdws8fSsF2q8HVJZx99Un-sU4q_FqYqz09wkj_CII9CHeAE65tpkt4rG_vcqNCBsdQCrk9IE8rdHzLIhG7UQSvN6Kzz1I4OqsYbatzPHrPUj7nYxsBJrxhGXjDKeh4Pl5ZGFDY5W5wGbnyG8vs_Bff5laCOnjPo60NKtZdfcfVj1Y-nB33bfvWFZA3Nq0vNk)
16. [droracle.ai](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQESFJogw4qtE2F1LUqm3M4cARXZ700naVcaJnf_fPXaPVl6xT8Ex0awnNyuWKWTV18nK4pWVkCCUDTpZZNtlscsamybF4ZWyyfFq5du59LH4BkCeCzH8l6WVb8e9tWo4M6XVv4OuN67YvMSIwhm7rmwUdqBbVOjVq3WBB2p_r3YWzJTov1OPPNOe81fsn1XQmwq-6CV1nYQa61Qa6rQ4eo=)
17. [claritytx.ai](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFR4JvHaIARUD5PP4KdpSXW5c0e6F2cu8WdqUpYAqqeL4MD9Wi__5p8iRiuLvUg1zuKqzIt9dLNiNJvSiMjTlGr2pawlwKxi8ltHWkvXI5OUt2FzzD2VEuYiCxKlJGuiD9G0tX_pH5VQ21mN8c9xSrxeGJvpvkyIAqza3usqigzcWgVN2OT)
18. [meonutrition.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGhciK6Kt2VZLvIgaR_yKaLY8JsN9QQCXPPowTAkOyDsFHAEdVzG3lWzZTeyB7m1LyRTA4LSBxHwTQ87vuI0Yq6Gy81UPf-G6HgSJl8pMCbT0IXGCrvvbHUQU1MF-OtKaCHCz7tDgVGX0yOAbV5n4TYFMK7)
19. [vitalwhys.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE5-OMVWrbIjiNRkrBKr09Ys1niQGJt3MopwbXiLk9RkjI92UxAhKJZCKeZjq2UnEXtZ_oShX_mYPKKhzu3f_QKSETbeFbM211BaAAusspTPNQwA-Y48ooWmg3Z5vhDIwjcS6gGzv5hKpZ0UKhDDB4MtLkIlasnBCA8xxiieTzb9NGk)
20. [singlecare.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFhSbPC26Mx_k0au5lORmDIaBkGr7WL6kTv6xWiUjjpH9st5sYyFs2tlF4IK4BLOMXkFPaIhHRrlq9mVn5wRtTCjIX9sIvwbcq6MdsvQ9X6frbj6fxbxdanmg-g1lgK0MaFfagDjvep2V0SUTbSYA==)
21. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHcJ7iCIO9iCOSFXJYY-ZBPuM_SbcAvZJqDj4h8ycyyWHrfdxZZTO-THu9ByQKpGt_DQ7_e1GeSFnLxZwibZYwOgPSpV-lFroMQtUZfl8PYlOlTk08253a0IRzJWYjk641bVMxjW5glDQ==)
22. [boltpharmacy.co.uk](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHUrJm3z4Lv-wRnRY6PnKGtivtAagByV1dvVCijDNgA_fZVxHdURF28PZQQBiiIQOl3zNho4ebTehz3os0_Xjx7Ay-8fyZRfoU1Rmgaf6JiCklaDp-fuIu085cFA8xA0p9DRZtTVEQX6EXhgqSv0mljxUa7OmwDaE3fydz0KFG-wFETTY7HeopB4aZkXnYC1KLU)
23. [herbiflix.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHedq97YRanJbCzg2NgtE8U_Sf50IOKHmprr6fSUg7Ietc1E9v9ubIjoCuzfhWYTyda0HpCyV0-Vl-wuaFr4wEuBZjXWVJZ1ojQ3dXMkRvF1b8i09Fu2DyaFlKjzDspD9GBsH9efZHkJJ_NMioRGsDtnizKm-O_oFcVp8p_Hes=)
24. [instalab.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwdpX1rnJl0xKcyxmweV1oY-EO9U29LxXON0Se_lBO2BjAvLx5PyQ0keIBnxSs3Y0pQgdeyC9Jw3jmciHX2AK52_KewsI7li18duy0qXUi0M3BnIW0jfcCPkGxOMVvBaIdPnighiFX7sQ=)
25. [droracle.ai](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH4xP3vZL9Ddt5wIe6n4HM9Sc5LpeyfxVTvjUviE6GXQMJUVrdnATOhr0gpwBh6r38NIQqch1UjW4Ou0pM31qq_r_HUCwhNyOd2VXUGO6vuLh61zMBQWR-blDLqdr2TFPsydqUKHoOmkIbuhCnPMQKzkcttNXUaHFL3DJxcu00mLFQbb_-cZG3lzV_n2vc3Pirv)
26. [buzzrx.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIbTzNzMy6PTJL8oXoOHst81xQo_v5tXHQw0JxCATU0_Z3XezR7TOKH3BC7fn2eRmyHdgYkfJZoLYJXjOv2ayzhQCg0brqwL91_TA1Q2Zmjd6WVhNJzUjYQIrGSst9-qrMYU8XghV2En0ARVe5NMBNFhHubOoYoa8DW0SKkVFsVKx-lB6M)
27. [mental-momentum.ai](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFbKACwkDGP20byS3oCoXCg2rpPXXRn0kTG8dD7r5q6QOZKizlVYda4_7vx8NqisVULWetyzsbJKTG9EuLG5n7NjAPxTxjDc6b1ZMwQaB_h_FNDQkpS7F9umG35AkJUUQrqIzztLLbxujUpgr10zauvxPEuCEv991QtzwG-TezYlE2UHfZgc0haQqHO)
28. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGZX4a4T5aV0sJrGZT7-WVd-ed7lMvv8n1erxbZXXn9HFXyO7iahSrItXVeR7gd4X1OMQNH8z-tKavcQsgn7s4e90F-TyDKx0AeUSPfcOtPhsw4XYmN1QMIRm6ShLatlvFoqZ-MLXy9kWb0gJx60yTX7VtTnj9ueDp6unu6ROmADGANuGnbhmUukQw8ZRyM2L8=)
29. [drruscio.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGI1S8uRV9kQWATzs55vseVXLLK4eQtfhFZpvIbeMwqTKGHtXNk9u3hBb4uaERWw3ALmPSDkshCi42fF68HiHMmJ43LmMJERNXbKPg4aaJC5KcAQSiCRL7HN6el7ycU0v4npg==)
30. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEWSOPzSsPJUjhnfJfjLqIVub0DxPX7NY4PYlC4YyoF2JA57Rzh0A4ZvkRslFOMQtWxDVrTj1dAIRIw_79gB-IV-bjNAY4-lG0sACsjkAAb0zsXw2W75dq6LgYSiZBVjQ==)
31. [theguardian.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQET-WLg6cUWbE1nauKGjdM5g_SKYDNj4ibb7l2PFrQBosViA_plVYQP1MdUO8DFG36MBgi-sbLaKQ2PLTPYWkmYofJyGbE7Nw401QIBcEpt2Ur5GsfHlMpSBjybCkygQ72Hkogjlwrn3MNnaAfAlpI8lZ4bIcK7geRLgegi4_7kF9xEo8fLnnlmZKCvYn7mJ0AvM_fXDA==)
32. [naturopathic.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHscfcu3rXYsMVZNyio59XnRzWwjbTljNcG3tnvPkXd80n8w0ACUsyEUgETVZKaENw7y1hcB7MgH-HASk0J2HasbaoKFxRsCsA1rrqkgqPaMK7Y7UclcWjxvDV5UKdcNSg4OHV41NSjIL6yqSR1vQrZShcGY48LG1QhRK9tJ1u3JYRtJXJf6eGRPuKxQWisZ7pXCUEporimH9h8YJ_IK7zi)
33. [healthfirsthagerstown.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGpnjV2S-LW0d_1Sy6bTRaxEz7okF2YyqBDuXUmVK4moEMveGAJnoMPyQrvlPDBc1hTm0AlIfuqZ3eA4RCjcT9Nk9hVKp4-vafDXYPul57_oHZmwIGujWvTjZPlquGT2w7LIqvNePwYgZKMjBgW9nVXNr84VaaJRD-3vyuNbNCbVEQlp7bxyj0cx1BBz1icsPiI1lJ7w3GXwGvVw_E=)
34. [plexusdx.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFldY8-2mMXRFoBHY7o9A9xuU4McjGR8NBRnpPaUwKbT6GR10H9FcdrIuDVh2yKMelzpupeCQg5RW3yhykyxmSe3xgQHwVuuSXExz1VkrslBg9ms1nEczjlKbmn3rZtnL86n6AmZYG6Zuy5eUJxVv2EGr7t9vgSEsr7Zo43ks7wqxxLF2zscS-H8AoCIQwMdiLYF_6MkaQFdObJmvsZ34zV5OsoYcHQo9JgfyHY8rT-Cuw=)
35. [faynutrition.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFzgq7TXSpVcMyUiJhQQCDslAeWoc0XOaQy1jz_C5_Gv4l7pvG12BtDQWKrs5hyY1DPQWKM0BWEdChYf1S-YTaF_b6i0FoyOREptCM3Q8bOSImPHAy7jMbS4TRU4uBhlPohmh2WxWEu1xmt4AMVw86TIfEIVV0kaEfd2VpOLxLaPA==)
36. [oregonstate.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFBx8g0Gcn3o5rAAz_ltZ6dPHN9wZoaM8ZXmceVd6IYgEaZIcFx2yBVK3j83PxuaWTU9GwCslFU33gpCPLMV-7OPDMb3fjkm-QKjVZaaL-9B5rBmT5l0BvHoDm6nnNrvRI7enWxXdALzYedP6MODRIWOqFDWsYvqiLVOIAlR_Ixdpk7DJlwgytHIsQehFC2OGrDm5mcfRGa6z7YPT6J30swpgZaJ0vl-Nkl2vu260v1)
37. [boltpharmacy.co.uk](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHGCwyK9_9fQTMqeLrmEEGyGSWuiJultm3dyiaq72GlEdjMF-0Mv_0prkrcgdcCeXXKxa0wqLISFg7yHwyVkKijxucATITB376kIPm6zLO1IyjtPDIg3DtoaoHUCnWxw0mVzJ7gq5I_fWOnwhwcC3k41q6u_w-ujnxvlq8lSgU=)
38. [eternalelixir.com.au](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGvYQiM5gA70FnNMutZSIz4EK8NutPGD72uRy-sbl49RB97Pe9hxUITOMN-L50aHlJEABJooaTb1NGt_eL5yLgrTMCYjNNZp4r-qV0BjMRwHoOskNyESwnB7enKcYWWQnGMPSBFLQPxuOWCAmH_9GQiVLYoR8YVXm0Z3rIEH8J0BG4HUDPmNevLLHb4Kw5_XT4VWgGE335GmnECyth6ICazTpkvFSxyT3dGOSkNmxY5VFNcXg==)
39. [droracle.ai](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEJfCY9DstdNnNHYbvX4KoQ7udJNkpKbrsQ98yEJL6HXTzrUI7m3o6ITJXawvMtI0Di-ymQg15I4VgZT9ECgA17ByT9TlTLyDyUuVDZKmua9-Sy0fW1KfDbj1jX-mqieSVDknV9hZO6MoAvnGZfC1Uv9ZGvuphAw5BypPHQ-8IqNJCueA1PgF39XoyJXlEHWjXb)
40. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFzb8gkApVpe3Tarv67kTE_--nZB5nOSM3swbYCe7Mpgv3Dm1WDNMmkM95aVCFu4QMQkjiWa_7mRr6yOe0_Q-4Zo_FX6E_OFtOobuWw1gdxY67M5_wOUVmQqeBN2JBCUw==)
41. [droracle.ai](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGUvHP1OOQcmbIMNqjXAWEE3HEvwDywkZH7V3E6EbmrBVC_Gk0rA62pvNbNPX0Jf5u6ZwWP47NqSerKoCmp2eU_V4RNNTIaof2uKuOqHPXP_pKdArw-sHc8C4YFMDrpEML7cCXlKOww0msqsuBVX8rPyiV0L7De2c0odSiQRyf-oduu_T-cNrXDiKRsT8o_s9byAg==)
42. [boltpharmacy.co.uk](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHcAFSqrnmeT8T_2tbJqXtDFkP0IX9BgvNxi-5q-hB-3rDO43J_f6RZ-QTnpwIRnY2E7nD7KaFCWm2noP-5u1cqzRjt-ooM84wt_O_c_ZhaeVNU-m9nnLAl3h9OEW8HLfQr6lC0KL9LkI37uDEei3JW68d88gYTT7YfB-VD)
43. [droracle.ai](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGOApR-fBSVpByUsFqYnS9_QA-DOZF6UN4e3uzbtYgpYnP4sZVtTXdodSyO9nATmXgv3cvI_9KTnxQaWKBwPk-CbPRZ6H0k5Nkbe5Av6K80rrTkPU7LoMqA71xrHxnQsoZEhZfnSos94NtCnhId90pJZj651qQGULcan5hqgQzlzg1EWD2qsEVbgJj_qWWDmlzHWmxlpA==)
44. [ubiehealth.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEfw98M24dZpSOouYqN-veFOlKfxL1JWIOUAWgQF8QC4lRVlVuJ0BqirCCjL30q9_wDBaZ4EnyvCJMPMugqtvo-8AwKR-H787U__QVV46wUkdjhA-wFOjgwbQIfKkTP1BHA5Xq9hfb2MlDVHafDd4UwYne5NTgxJVir9Ln5v7KgxPMfG-ic6xURCGGivs9BRrM=)
45. [apkamuaalij.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHn0LZ__bGkyYamrgDI-S5XJ72KjpnMW6hzNGoMfPBBJRahMgpvNgPECbGGy5dGimxg1lNw7U7X18vAqElLz8ljKtHYjqmI7L_IKkMZavc0Y3qDA4rBfIZXSHoW-zgUd4AGZTP1yJQ6rz5NWHRxWG-pC5atKzKP3rP2EqebhMtiZwlz)
46. [faynutrition.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHErMZLK43DTnhM9w5CVhU6qFUIeMAydiBCJYbFiIaACDVrK_IN4Gi3BsLYiUPMpXc2HQM-r7mALISgK2FTwEItuIw8TjPmIQ3JAVvAmeHjOcNEJpEmEQ2V86IQYY9J6SzcB8eq4vtNpAw7wDP7iW_qIcTJAzpCqKhsnTMfVgzDmFiqQYF4lo0pj-4nVD5f1VXcjyjbILW2XyJZ)
47. [kathmandu.gov.np](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHJjW1AeiDIkg-xOFZXVSmauyrIqlKcUx2n8iCojkiXaP9AXTYWaakKyVEc63wQ1x0KPOLX081OD5XfD1ufLjt6o_mwFuDYNuzQHoPRcaqVngDZJfGgnSSIgqshpSbJ-jmOr4BoELyeoIvegB16tKnNNHdgcRm44vowOwuILm2r2BaXExjqUmuN7OGEuMWkCJbouH1Z80Bcud0Fvmyk9zTLSGzlxi8=)
48. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDbCMOxW0mvtyBWq3pKeK7F8vzjNznPxdJ2A94bAqbdbZVHqY3C70KNdBny0vq2N9Y3uUA9YVUqbtxkqNlh9PCE9YNdM0pnXzYxETGGbmr7K4vvIf3EuubL66FJh_I2jImMvl5AY72uQ==)
49. [landyschemist.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEGYy9rIpBthmE40CU2vKsblRdnT0ESuZCwS9xxn0vuyFmsdhM-8ZiR9BRJbXf4IjZIgjfNNDrqap71mfTa0R2rwCFZAi1y4ArgcAqKIfkAaCT6puLTHfdp3USmZiluzJROy__713Zelw0NeFDlHBRYDF6bECQ=)
50. [swisspeakhealth.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFxtV_cEHL9J19ajm_rnLPuUy99Qd48S5DSIVSRg9JMHnx0AtfftufkmfDMetimxJmNZp05YQ9OTf3g1-16e2JLyr0F08CECVJZfIJsFZCb6fuhUTZuh6zue4JoI9KKue-F2XE1zKfUh4sLRVhg9zGjBs1dXx0R3OkNswSQdrugZToocIyeyRWkBHYEAvY4u8bryydh_l_6yGO4T99D7tW0)
51. [naturemade.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE1GC49ifqTiPAMXE5bamjXuiGK_fGsa4PurmORnI8LO01YLNnrLyg0sY0rQdV30xeMh8b3vp4KqIzUVW5kryvNnOIxlLQRVWQ-Zp6-8T5CR2ASYUFhiREQZHECZzEh6TG0VDxJvSvW9YAHuSn_P6Y5DXD_AI6BSs2BNMk4hkw3dsOSt0lW3kkN6L1o)
52. [iherb.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHUuK3kbY69nj35UiW7v7T_KGJMNCxZ91yxprtLdZH8LGMESJOFbNR_C6sOIoYuIm5S9kHTdFa3IiFoBhKwPS9jbiEev8fLpbtu7mFho2-q-23p6rKHZ5mDCWuso8fAURdLj5vS0o6UhMojvGxARw==)
53. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGirft4_3M3sJm4cWvDe-mk0z8awsRnS-hJhxZldxnuGCDuQ1iMM0x6sBI_yqAyxhGCPUazCC2N3OiRLa3oCFzL9AG81iHS6saD4_zMFtjmeIzliyUKUolE0U6st2dEq2eh21ooke_VIXTyKHdbSUSEfT32lr3PtApzImdxpuDqwVjqRMmHYS5o7cf8GvDy9js=)
54. [yourhealthier.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGvMyEh1Wb5nBA3-voYBBd8ssw9ci-bzhFQ5aw5UtmhSNqfdNApS4MYm5ktf-NoIWSrGWlYFC_tnisfg4GPpPoL9MJAvaHjR494B-PZ9UPEu3_HvMA06f43nQPkDlT9QoWZBJC54uclbbFGGSNmLq2XZA==)
55. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGeCmdspB2UNhA_aqqk86Qs_cC1BcT9xSyb4IXYFAhPNkyC8_pDWcSBtJUXd4z17APK2wKLJH_Pea8ZZ4NEGnfOVxWbSDHzMtsCu08JysCNAhcZ0O0_Rk9-7vfMPXgj7Rd5n50xtBLvI4ZkeHwRCSWvkmdYMNC1Cf029ayCNr4fgTyZo3DVVmx2E-YqVXIeQuFPGVLoghzmd_ctkWz1VPglAoLTb9BrQFjd1CkoVV7LIz--9PAMM_PyyMG0XlMPQigFXUF5QA==)
56. [e-cmh.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF6oNKcboGFI7YQNdtMcegHWjljb49CH4Ot6wmC2i9gQHN9ciFEa6BZ0UGZFhQUiKameMw_XlHjkEHJatgXAWiJUd0_M0Kc1-0mqg7lP7PD1nqLzSMhhtBzz_AL0xmHQTFr1jZvCERLqtLBk4rfbxTMAaq-HHVc)
57. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGFyJi2j4QlKMIH0kkF6lLS-98hYiedlsFYu8-EaVwVg9-kfwTTY1TvnSaqjiBnwPjW8IjNGj6fwhwMwbBvQyHDXhZtu20eBMpRgfK4tYJdiBGajWrApFGRRfDrZ-UFIGgn5c7CMxypeQ==)
58. [droracle.ai](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEz8Ripsg5nu0bio9A3wcohqBmZzdlGsx_mWwX8vpmh8ASZHOT561fANiKWl098Ja89FJxL2QxSZV8N_wo61oCqGpz7zI_TouyGlln87J1sKGvoyhyELpBy5wCsURRjekCM04OHtgP7geY7HrluYZCwove01YUYaFDmluoYSpDW4ACPuRxUiLK_XfCFs4d-M-nvohM=)
59. [droracle.ai](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGnzfw2zlkXk1nBz8oTFTo7eEZzc_1xafb9NR4fHqzKHmp9Wy8pDUfOK-4QFTXIxQPE0SdG_Mp6vAH-j_rcPjCXGySKRFxG5ByIKJq0mJ077HiX1s8oWvv9lBp51Hd4FojcSJgYrpbL9DNdVQni62-cl17SRVq4J63bHTMsU3GCnB8G7vCwfmh5bpk5JA==)
60. [fellahealth.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGOPglgWiGLa2ov4sEmnSprFtzxU9qRqI75y3xO1gU_wxZpIo6vWJ_Sgncu1t4-rHLBAnKe5GzuTFyjRqKodnpIuoTIXreBAsMTH2i7h5OKJ_gu-3ebLpBCNxPJ6xPaKsBS8g0xJ82eXonNkvctnJwr6cZJMQ==)
61. [cam.ac.uk](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHoRhXp6xU-hTulkLZ6CJrbUwpChHPShoHIHqy6aZsLtV_yvkREkvh091we-SFVbn89GoqOSkNvtitKuHOiygaFTX58xvZZwa0ussHv1kSy_NzZIrP1tfZ8pkK1BwgbF-Mwvv6YZkIuWeUNeUyEPBjO5ip1UTDyEGMMVnOREskvmvjJsvoJMB_eFplQIhxnbMo6wKJl0FxPwwhBpzaNGFKo2RFBjHwiMSR7uPEaDGx7QYXVHHcH9mH6z0SIerpWOt1dxjF-FBHdPKRtvDeYQbkVDUK1m9Kg3g==)